Medpace Holdings, Inc. (NASDAQ:MEDP) Receives Consensus Recommendation of “Reduce” from Analysts

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have been assigned a consensus rating of “Reduce” from the sixteen research firms that are covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $422.2727.

A number of research analysts recently issued reports on the stock. Rothschild & Co Redburn cut shares of Medpace from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $342.00 to $474.00 in a research note on Wednesday, September 3rd. Robert W. Baird lifted their price objective on shares of Medpace from $313.00 to $490.00 and gave the company a “neutral” rating in a research note on Wednesday, July 23rd. Jefferies Financial Group lifted their price objective on shares of Medpace from $400.00 to $450.00 and gave the company a “hold” rating in a research note on Tuesday, September 9th. Barclays raised their target price on shares of Medpace from $300.00 to $450.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 23rd. Finally, UBS Group lowered shares of Medpace from a “neutral” rating to a “sell” rating and raised their target price for the company from $300.00 to $305.00 in a research report on Tuesday, July 29th.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $501.94 on Friday. The company’s 50 day simple moving average is $443.38 and its 200 day simple moving average is $353.86. The stock has a market capitalization of $14.10 billion, a price-to-earnings ratio of 37.32, a price-to-earnings-growth ratio of 3.13 and a beta of 1.44. Medpace has a 1 year low of $250.05 and a 1 year high of $506.55.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.10. The business had revenue of $603.31 million for the quarter, compared to analysts’ expectations of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The firm’s quarterly revenue was up 14.2% compared to the same quarter last year. During the same period last year, the firm posted $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, analysts anticipate that Medpace will post 12.29 EPS for the current fiscal year.

Insider Transactions at Medpace

In other Medpace news, CFO Kevin M. Brady sold 12,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $454.23, for a total value of $5,450,760.00. Following the sale, the chief financial officer owned 6,000 shares in the company, valued at $2,725,380. This trade represents a 66.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Susan E. Burwig sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the completion of the sale, the vice president owned 57,500 shares in the company, valued at $27,600,000. This represents a 14.81% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 161,266 shares of company stock valued at $74,111,427. Corporate insiders own 20.30% of the company’s stock.

Institutional Trading of Medpace

A number of hedge funds have recently added to or reduced their stakes in MEDP. Invesco Ltd. lifted its holdings in shares of Medpace by 9.4% during the first quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock worth $361,596,000 after purchasing an additional 102,015 shares during the period. Wasatch Advisors LP lifted its holdings in shares of Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after purchasing an additional 116,354 shares during the period. Mawer Investment Management Ltd. lifted its holdings in shares of Medpace by 17.4% during the second quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock worth $256,559,000 after purchasing an additional 121,213 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Medpace by 15.1% during the second quarter. AQR Capital Management LLC now owns 621,184 shares of the company’s stock worth $193,269,000 after purchasing an additional 81,637 shares during the period. Finally, Bessemer Group Inc. lifted its holdings in shares of Medpace by 1.1% during the first quarter. Bessemer Group Inc. now owns 582,269 shares of the company’s stock worth $177,411,000 after purchasing an additional 6,225 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.